<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00093483</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000387999</org_study_id>
    <secondary_id>P30CA016056</secondary_id>
    <secondary_id>RPCI-RP-0209</secondary_id>
    <nct_id>NCT00093483</nct_id>
  </id_info>
  <brief_title>Arsenic Trioxide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia</brief_title>
  <official_title>Arsenic Trioxide, High-Dose Cytarabine and Idarubicin Induction Therapy in Previously Untreated de Novo and Secondary Adult Acute Myeloid Leukemia Patients &lt; 60 Years Old - A Phase I Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Roswell Park Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Roswell Park Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as arsenic trioxide, cytarabine, and idarubicin,&#xD;
      work in different ways to stop cancer cells from dividing so they stop growing or die.&#xD;
      Combining more than one drug may kill more cancer cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of arsenic trioxide&#xD;
      when given together with cytarabine and idarubicin in treating patients with acute myeloid&#xD;
      leukemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the maximum tolerated dose and/or biologically effective dose of arsenic&#xD;
           trioxide followed by high-dose cytarabine and idarubicin in patients with previously&#xD;
           untreated de novo or secondary acute myeloid leukemia.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of arsenic trioxide. Patients are stratified&#xD;
      according to timing of accrual (before November 2002 vs since November 2002).&#xD;
&#xD;
      Patients receive arsenic trioxide IV over 1 hour on day 1 followed by high-dose cytarabine IV&#xD;
      over 1 hour every 12 hours on days 1-6 and idarubicin IV over 30 minutes on days 2-4&#xD;
      (immediately after doses 3, 5 and 7 of cytarabine). Patients also receive filgrastim (G-CSF)&#xD;
      subcutaneously beginning 12 hours after the last dose of chemotherapy and continuing until&#xD;
      blood counts recover.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of arsenic trioxide until the maximum&#xD;
      tolerated dose (MTD), current dose used for myelodysplastic syndromes or acute promyelocytic&#xD;
      leukemia, or biologically effective dose is reached. The MTD is defined as the dose preceding&#xD;
      that at which 2 of 6 patients experience dose-limiting toxicity. The biologically effective&#xD;
      dose is defined as the dose at which 3 patients with constitutive STAT3 activity have the&#xD;
      activity negated after the first dose of arsenic trioxide.&#xD;
&#xD;
      PROJECTED ACCRUAL: A maximum of 40 patients (6 for stratum I [accrued before November 2002]&#xD;
      and 34 for stratum II [accrued since November 2002] will be accrued for this study within 3&#xD;
      years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2002</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose and/or biologically effective dose or arsenic trioxide</measure>
    <time_frame>30 days after completion of study treatment</time_frame>
  </primary_outcome>
  <enrollment type="Actual">61</enrollment>
  <condition>Leukemia</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <description>Subcutaneously beginning 12 hours after the last dose of chemotherapy and continuing until blood counts recover.</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>arsenic trioxide</intervention_name>
    <description>IV over 1 hour on day 1</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
    <description>IV over 1 hour every 12 hours on days 1-6</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>idarubicin</intervention_name>
    <description>IV over 30 minutes on days 2-4 (immediately after doses 3, 5 and 7 of cytarabine).</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed de novo or secondary acute myeloid leukemia with ≥ 20% blasts&#xD;
             AND at least 1 of the following characteristics*:&#xD;
&#xD;
               -  Auer rods&#xD;
&#xD;
               -  Peroxidase or sudan black positive blasts&#xD;
&#xD;
               -  Chloroacetate esterase-positive or diffusely non-specific esterase-positive&#xD;
                  blasts&#xD;
&#xD;
               -  Presence of a myeloid immunophenotype by multiparameter flow cytometry, including&#xD;
                  expression of one or more myeloid markers (CD13, CD33) on blasts NOTE:&#xD;
                  *Megakaryocytic leukemia can be diagnosed by the detection of platelet antigens&#xD;
                  (e.g. factor VIII, glycoprotein Ib or IIb/IIIa) using monoclonal antibodies or&#xD;
                  the presence of ultrastructural platelet peroxidase&#xD;
&#xD;
          -  No acute promyelocytic leukemia&#xD;
&#xD;
          -  No Philadelphia-chromosome positive chronic myeloid leukemia&#xD;
&#xD;
          -  Prior hematologic disorders, including myelodysplastic syndromes, aplastic anemia,&#xD;
             paroxysmal nocturnal hemoglobinuria, and myeloproliferative disorders allowed&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 to 59&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  More than 4 weeks&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin ≤ 2 times normal*&#xD;
&#xD;
          -  SGOT ≤ 2 times normal*&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 2 times normal* NOTE: *Unless abnormalities are directly&#xD;
             attributable to leukemia&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 1.5 times normal* NOTE: *Unless abnormalities are directly attributable&#xD;
             to leukemia&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  Cardiac ejection fraction ≥ 45%*&#xD;
&#xD;
          -  Absolute QT interval ≤ 460 msec with potassium &gt; 4.0 mEq/L and magnesium &gt; 1.8 mg/dL&#xD;
&#xD;
          -  No myocardial infarction within the past 6 months&#xD;
&#xD;
          -  No uncontrolled symptomatic congestive heart failure&#xD;
&#xD;
          -  No angina pectoris&#xD;
&#xD;
          -  No multifocal cardiac arrythmias&#xD;
&#xD;
          -  No other severe cardiovascular disease NOTE: *Unless abnormalities are directly&#xD;
             attributable to leukemia&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No serious medical or psychiatric illness that would preclude informed consent or&#xD;
             limit survival to &lt; 4 weeks&#xD;
&#xD;
          -  No uncontrolled diabetes mellitus&#xD;
&#xD;
          -  No other concurrent active malignancy&#xD;
&#xD;
          -  No known hypersensitivity to E. coli-derived drug preparations&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 3 months after study&#xD;
             participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No prior chemotherapy for acute leukemia, except hydroxyurea to control white blood&#xD;
             cell counts&#xD;
&#xD;
               -  Prior chemotherapy for an antecedent malignancy or other medical condition&#xD;
                  allowed&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Prior radiotherapy for an antecedent malignancy or other medical condition allowed&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Meir Wetzler, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Roswell Park Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <study_first_submitted>October 6, 2004</study_first_submitted>
  <study_first_submitted_qc>October 7, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2004</study_first_posted>
  <last_update_submitted>January 10, 2014</last_update_submitted>
  <last_update_submitted_qc>January 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 13, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adult acute basophilic leukemia</keyword>
  <keyword>adult acute eosinophilic leukemia</keyword>
  <keyword>adult erythroleukemia (M6a)</keyword>
  <keyword>adult pure erythroid leukemia (M6b)</keyword>
  <keyword>adult acute megakaryoblastic leukemia (M7)</keyword>
  <keyword>adult acute minimally differentiated myeloid leukemia (M0)</keyword>
  <keyword>adult acute monoblastic leukemia (M5a)</keyword>
  <keyword>adult acute monocytic leukemia (M5b)</keyword>
  <keyword>adult acute myeloblastic leukemia with maturation (M2)</keyword>
  <keyword>adult acute myeloblastic leukemia without maturation (M1)</keyword>
  <keyword>adult acute myelomonocytic leukemia (M4)</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>untreated adult acute myeloid leukemia</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Idarubicin</mesh_term>
    <mesh_term>Arsenic Trioxide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

